Breaking News

Abzena Completes ADC Tech Transfer

Successful technical transfer of Synaffix GlycoConnect ADC Technology to enable use in client projects

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abzena has completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect (antibody conjugation) and HydraSpace (highly polar spacer). Familiarity with these antibody-drug conjugate (ADC) technologies adds to Abzena’s expertise in process development and GMP manufacturing of ADC linkers and payloads. Abzena can now rapidly ramp up ADC projects using Synaffix technology with high scientific quality.   “Abzena believes in patient first drug development,”...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters